List view / Grid view
27 May 2015 | By Victoria White
The SCALE Obesity and Prediabetes trial met its primary endpoint, demonstrating that ongoing treatment with Saxenda delayed the onset of type 2 diabetes...
26 May 2015 | By Victoria White
The South Asian Health Foundation (SAHF) has been named ‘Diabetes Team of the Year’ at the prestigious 2015 BMJ Awards...
11 May 2015 | By Victoria White
Data from a post-hoc analysis of a Phase 3a trial demonstrates the weight-loss-dependent and independent effects of liraglutide 3 mg...
14 April 2015 | By Victoria White
The Changing Diabetes in Children programme, a scheme that has provided free insulin to 13,000 children since 2009, has been extended by three years.
13 April 2015 | By Victoria White
Novo Nordisk has opened a manufacturing facility in the Kaluga region of Russia for formulation and filling of modern insulin for the treatment of diabetes...
27 March 2015 | By Victoria White
Novo Nordisk has announced that it has decided to resubmit New Drug Applications of Tresiba and Ryzodeg to the FDA within the month.
11 March 2015 | By Novo Nordisk
Latest data announced at Diabetes UK reinforces the long-term efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes...
9 March 2015 | By Novo Nordisk
New data from the phase 3a SCALE™ Obesity and Prediabetes trial were presented at The Endocrine Society’s 97th Annual Meeting (ENDO), showing that adults with obesity or who are overweight with comorbidities who had lost ≥5% of their body weight at 56 weeks (ie weight loss responders), demonstrated greater improvements…
21 January 2015 | By Aurora
A once daily injection has been approved for adults with type 2 diabetes and moderate renal impairment (stage 3 chronic kidney disease) in the UK...
19 January 2015 | By Novo Nordisk
Novo Nordisk announced Switzerland as the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes...
9 December 2014 | By Novo Nordisk
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment...
1 October 2014 | By DKSH Business Unit Healthcare
DKSH, the leading Market Expansion Services provider with a focus on Asia, signed an agreement to provide commercial and distribution services to Novo Nordisk, a global healthcare company with 90 years of experience in diabetes care, in Malaysia...
26 September 2014 | By Novo Nordisk
Novo Nordisk announced that the company will establish a new obesity research unit in Seattle, Washington, in the US...
19 September 2014 | By Novo Nordisk
New analyses of Phase 3a IDegLira (insulin degludec /liraglutide; Xultophy®) DUAL™ study data show an early and substantial improvement in glycaemic control, and a beneficial weight profile in type 2 diabetes patients compared to insulin degludec...
3 September 2014 | By Novo Nordisk
The Lancet Diabetes & Endocrinology has published the phase 3a DUAL™ I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) − once-daily, single injection insulin degludec (Tresiba®▼ ) and liraglutide (Victoza®)...
